An experimental injection for abdominal fat reduction is entering Phase 3 testing, offering a different approach from weight-loss drugs such as Ozempic.

Called CBL-514, the experimental injection is designed to reduce fat beneath the skin by triggering apoptosis, or programmed cell death, in fat cells near the injection site. Unlike weight-management drugs, it is being developed for localised fat reduction rather than overall weight loss.

In a Phase 2 trial, 69.6% of the CBL-514 participants assessed at the eight-week follow-up (16 of 23) had at least 150 millilitres less abdominal subcutaneous fat than at baseline.

A Phase 3 trial involving an estimated 320 adults is now evaluating the injection's safety and effectiveness.

How CBL-514 Differs From Ozempic

Ozempic contains semaglutide, which activates GLP-1 receptors involved in blood sugar regulation and appetite. It helps control blood sugar, slows stomach emptying and reduces appetite, supporting weight loss.

Although losing weight can reduce abdominal fat, semaglutide does not specifically target or destroy fat cells in one area.

CBL-514 takes a different approach. The experimental injection is designed to promote apoptosis, or programmed cell death, in adipocytes (fat cells) around the injection site.

While Ozempic is primarily used to treat type 2 diabetes, semaglutide is also sold under other brand names for weight management. CBL-514 is being studied as a targeted treatment for abdominal fat, not general weight loss.

What the Phase 2 Trial Found

A 2025 study published in the Aesthetic Surgery Journal examined CBL-514 in 76 participants. They were randomly assigned to receive either the injection or a placebo, with up to four treatments administered four weeks apart.

Eight weeks after their final treatment, 69.6% of the assessed CBL-514 group had achieved at least 150 millilitres of abdominal subcutaneous fat-volume reduction. This represented 16 of 23 participants, compared with none of the 16 assessed in the placebo group.

The researchers also found that 60.9% of the assessed CBL-514 group, or 14 of 23 participants, achieved at least 200 millilitres of fat-volume reduction.

Subcutaneous fat is stored directly beneath the skin. It differs from visceral fat, which surrounds internal organs deeper inside the abdomen. The trial investigated subcutaneous fat reduction, not the removal of visceral fat.

The findings are encouraging but have limitations. The study was small, nearly half of participants did not complete it, and follow-up lasted only eight weeks after treatment. The researchers said longer studies are needed to establish how long the effects last.

Phase 3 Trial Will Assess Safety and Effectiveness

The next stage involves approximately 320 adults with moderate or severe abdominal fat. The Phase 3 SUPREME-01 trial began on 1 September 2026 and is testing up to four abdominal treatments, administered at four-week intervals.

Safety remains an important consideration. In the Phase 2 study, injection-site reactions, including pain, redness, itching and swelling, were common. Most were mild or moderate, but nine participants in the CBL-514 group reported severe treatment-related adverse events, all involving injection-site pain.

Two participants also stopped treatment because of treatment-related injection-site pain and discolouration.

CBL-514 remains experimental and has not been established as an approved treatment for abdominal fat reduction. Its Phase 3 results will be needed to provide stronger evidence about its effectiveness and safety.

Until further evidence is available and regulators assess the findings, it should not be considered a proven alternative to weight-management medication or established fat-reduction procedures.